GlassScriptPhysician profile
Marissa Love
NPI 1427494202
$4,212.87
in general payments reported to CMS, 2019-2025
25 companies · $1,138 in 2025
The $1,138 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2023: $366 · 2024: $2,510 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,752 · Travel and Lodging: $1,247 · Consulting Fee: $15.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,751.50 |
| Travel and Lodging | $1,247.27 |
| Consulting Fee | $15.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,952.32 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Astrazeneca Uk Limited | $398.24 | 2024 | Airsupra |
| Regeneron Healthcare Solutions, INC. | $347.00 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $280.64 | 2019-2025 | Trelegy Ellipta, Nucala |
| Pfizer INC. | $146.56 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.08 | 2024-2025 | Hyqvia, Takhzyro |
| Genzyme Corporation | $124.45 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $122.30 | 2023 | Orladeyo |
| Aquestive Therapeutics, INC. | $119.22 | 2025 | |
| Grifols USA, LLC | $117.52 | 2024-2025 | Xembify |
| Blueprint Medicines Corporation | $106.99 | 2025 | Ayvakit |
| Amgen INC. | $59.28 | 2024-2025 | Tezspire |
| Csl Behring | $39.50 | 2024-2025 | Hizentra, Andembry |
| Hospira, INC. | $38.13 | 2024-2025 | |
| Genentech USA, INC. | $37.15 | 2025 | Xolair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $28.20 | 2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $23.12 | 2025 | |
| Cycle Pharmaceuticals INC | $23.00 | 2025 | Sajazir |
| Hikma Pharmaceuticals USA | $18.11 | 2024 | Ryaltris |
| Kedrion Biopharma, INC. | $17.73 | 2025 | Rhogam Ultra-Filtered Plus, Gammaked, Albuked |
| Ionis Pharmaceuticals, INC. | $16.14 | 2025 | Dawnzera |
| Optinose US, INC. | $15.74 | 2025 | |
| Adma Biomanufacturing LLC | $15.07 | 2025 | |
| Incyte Corporation | $14.06 | 2024 | Opzelura |
| Exact Sciences Corporation | $13.32 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.